Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271514 | 1.00 | CTSK (0.60) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL3498624 | 0.92 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL28907829 | 0.92 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL1261148 | 0.92 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL19015799 | 0.87 | CTSK (0.53) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL1690906 | 0.85 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL18428122 | 0.85 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL1262565 | 0.85 | CTSK (0.62) | CTSKCYP2D6CA2CA1CA7 | |
| SCHEMBL22525990 | 0.84 | CTSK (0.61) | CTSKCA2CA1CA7 | |
| SCHEMBL18471584 | 0.84 | CTSK (0.61) | CTSKCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | disclosed |
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | disclosed |
| US-20220073475-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIVERSITÉ PARIS CITÉ (FR) | 2022-03-10 | — | — | US | disclosed |
| WO-2020148403-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIVERSITE DE LILLE (FR) | 2020-07-23 | — | — | WO | disclosed |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
| CN-101432129-A | Novel compounds that are useful for improving pharmacokinetics | ABBOTT LAB (US) | 2009-05-13 | — | — | CN | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | CTSK 137/4885CYP2D6 2204/4885CA2 1628/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CTSK 2452/4885CYP2D6 23/4885CA2 953/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CTSK 90/4885CYP2D6 1664/4885CA2 788/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CTSK 83/4885CYP2D6 1923/4885CA2 2028/4885 |
| US-20220073475-A1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | HDAC5, HDAC6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CTSK 1190/4885CYP2D6 294/4885CA2 691/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CTSK 83/4885CYP2D6 1923/4885CA2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.